StockNews.com started coverage on shares of Quotient (NASDAQ:QTNT – Get Rating) in a research note issued to investors on Sunday morning. The firm issued a hold rating on the stock.
A number of other brokerages have also commented on QTNT. Cowen decreased their price target on shares of Quotient from $9.00 to $3.00 and set an outperform rating on the stock in a report on Wednesday, June 29th. BTIG Research reduced their target price on shares of Quotient from $9.00 to $1.50 and set a buy rating on the stock in a report on Wednesday, June 29th. Finally, Cowen reduced their target price on shares of Quotient from $9.00 to $3.00 and set an outperform rating on the stock in a report on Wednesday, June 29th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $2.25.
Get Quotient alerts:Quotient Price Performance
Shares of NASDAQ:QTNT opened at $0.15 on Friday. The company's fifty day moving average price is $0.22 and its 200-day moving average price is $0.46. The firm has a market capitalization of $14.97 million, a price-to-earnings ratio of -0.11 and a beta of 2.76. Quotient has a one year low of $0.14 and a one year high of $3.19.
Quotient (NASDAQ:QTNT – Get Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.09). The firm had revenue of $8.81 million for the quarter, compared to analysts' expectations of $9.40 million. As a group, equities research analysts expect that Quotient will post -0.69 EPS for the current year.Insider Buying and Selling at Quotient
In other news, Director Prondzynski Heino Von purchased 700,000 shares of the company's stock in a transaction on Thursday, September 15th. The stock was acquired at an average price of $0.20 per share, with a total value of $140,000.00. Following the transaction, the director now directly owns 1,405,879 shares of the company's stock, valued at approximately $281,175.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 984,808 shares of company stock valued at $195,354 in the last quarter. Company insiders own 10.50% of the company's stock.
Institutional Investors Weigh In On Quotient
Several institutional investors have recently added to or reduced their stakes in the company. Walleye Capital LLC boosted its position in Quotient by 4,136.3% during the 2nd quarter. Walleye Capital LLC now owns 3,000,000 shares of the company's stock valued at $720,000 after buying an additional 2,929,184 shares during the period. Millennium Management LLC purchased a new stake in shares of Quotient in the 2nd quarter worth about $343,000. JPMorgan Chase & Co. lifted its position in shares of Quotient by 9,156.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,491,154 shares of the company's stock worth $838,000 after purchasing an additional 3,453,439 shares during the period. State Street Corp lifted its position in shares of Quotient by 8.1% in the 1st quarter. State Street Corp now owns 1,502,911 shares of the company's stock worth $1,803,000 after purchasing an additional 112,013 shares during the period. Finally, Clearbridge Investments LLC lifted its position in shares of Quotient by 0.8% in the 1st quarter. Clearbridge Investments LLC now owns 4,255,908 shares of the company's stock worth $5,107,000 after purchasing an additional 33,409 shares during the period. Hedge funds and other institutional investors own 86.84% of the company's stock.
Quotient Company Profile
(Get Rating)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.
See Also
- Get a free copy of the StockNews.com research report on Quotient (QTNT)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.